Elacestrant dihydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for elacestrant dihydrochloride and what is the scope of patent protection?
Elacestrant dihydrochloride
is the generic ingredient in one branded drug marketed by Stemline Therap and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Elacestrant dihydrochloride has one hundred and five patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for elacestrant dihydrochloride
International Patents: | 105 |
US Patents: | 8 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 11 |
Patent Applications: | 37 |
DailyMed Link: | elacestrant dihydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for elacestrant dihydrochloride
Generic Entry Date for elacestrant dihydrochloride*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for elacestrant dihydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Menarini Group | Phase 3 |
Breast International Group | Phase 3 |
European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
Pharmacology for elacestrant dihydrochloride
Drug Class | Estrogen Receptor Antagonist |
Mechanism of Action | Breast Cancer Resistance Protein Inhibitors Estrogen Receptor Antagonists P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for elacestrant dihydrochloride
US Patents and Regulatory Information for elacestrant dihydrochloride
International Patents for elacestrant dihydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1251407 | 治療癌症的方法 (METHODS FOR TREATING CANCER) | ⤷ Try a Trial |
Hong Kong | 1251408 | 治療癌症的方法 (METHODS OF TREATING CANCER) | ⤷ Try a Trial |
Japan | 2018514549 | 癌を治療するための方法 | ⤷ Try a Trial |
Canada | 2984357 | PROCEDES DE TRAITEMENT DU CANCER (METHODS FOR TREATING CANCER) | ⤷ Try a Trial |
European Patent Office | 3122426 | MÉTHODE DE TRAITEMENT DU CANCER FAISANT INTERVENIR DES MODULATEURS SÉLECTIFS DES RÉCEPTEURS DES OESTROGÈNES (METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS) | ⤷ Try a Trial |
Brazil | 112017023228 | métodos para tratamento de câncer | ⤷ Try a Trial |
Mexico | 2021005561 | RAD1901 PARA USARSE EN EL TRATAMIENTO DE CANCER EN SUJETOS CON CANCER POSITIVO A RECEPTOR DE ESTROGENO ALFA RESISTENTE A FARMACO. (METHODS OF TREATING CANCER.) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for elacestrant dihydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3122426 | 301263 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/23/1757 20230918 |
3122426 | LUC00331 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
3122426 | CA 2024 00007 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OR A SALT THEREOF; REG. NO/DATE: EU/1/23/1757 20230918 |
3122426 | PA2024504 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANTAS ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1757 20230915 |
3122426 | 2024C/505 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ELACESTRANT OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1757 20230918 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.